exenatide (byetta) Report issue

Biologics Peptide Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Exenatide (exendin-4) is sold under the brand name BYETTA to improve glycemic control in people with type 2 diabetes mellitus. Exenatide is a glucagon-like peptide 1 (GLP-1) receptor agonist that enhances glucose-dependent insulin secretion by the pancreatic beta cell, suppresses inappropriately elevated glucagon secretion, and slows gastric emptying. The drug also moderates peak serum glucagon levels during hyperglycemic periods following meals but does not interfere with glucagon release in response to hypoglycemia.   NCATS

Chemistry

  • SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H](N)Cc3cnc[nH]3)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc4c[nH]c5ccccc45)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)NCC(=O)NCC(=O)N6CCC[C@H]6C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N7CCC[C@H]7C(=O)N8CCC[C@H]8C(=O)N9CCC[C@H]9C(=O)N[C@@H](CO)C(=O)N
  • InChIKey: HTQBXNHDCUEHJF-XWLPCZSASA-N
  • Mol. Mass: 4186.64
  • ALogP: Missing data
  • ChEMBL Molecule:
    exenatide  
More Chemistry

Pharmacology

  • Mechanisms of Action:
  • Multi-specific: No
  • Black Box: Yes
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

Australia

$42.5717 - $60.8223

United States

$127.1150 - $721.0500
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

ac002993 | ac2993 | ac 2993 | ac-2993 | ac2993a | ac 2993 lar | bydureon | byetta | ex4 peptide | exantide | exenatide | exenatide synthetic | exendin 4 | exendin-4 | itca 650 | pb-119 | rexenatide | spil1033 | synthetic exendin-4

Organizations (172)

Research & Development (172)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (68)

Approved Indications (1)


 

Diabetes Mellitus, Type 2

Experimental Indications - Clinical Trial Phases 1-4 (68)


 

Acute Coronary Syndrome (Phase 4)

Alcohol-Induced Disorders (Phase 2)

Alcoholism (Phase 2)

Atherosclerosis (Phase 4)

Autoimmune Diseases (Phase 1/Phase 2)

Blood Glucose (Phase 4)

Bone Remodeling (Phase 4)

Brain Injuries (Phase 4)

Burns (Phase 2/Phase 3)

Cardiovascular Diseases (Phase 4)

Cocaine-Related Disorders (Phase 1/Phase 2)

Cognition Disorders (Phase 3)

Coronary Artery Disease (Phase 3)

Coronary Restenosis (Phase 4)

Craniopharyngioma (Phase 3)

Deficiency Diseases (Phase 4)

Diabetes Complications (Phase 2)

Diabetes, Gestational (Phase 4)

Diabetes Insipidus, Neurogenic (Phase 4)

Diabetes Mellitus (Phase 4)

Diabetes Mellitus, Type 1 (Phase 4)

Diabetes Mellitus, Type 2 ()

Diabetic Nephropathies (Phase 4)

Diet, Ketogenic (Phase 4)

Endothelium (Phase 4)

Fatty Liver (Phase 4)

Glucose Intolerance (Phase 4)

Healthy Volunteers (Phase 4)

Heart Failure (Phase 4)

Heart Failure, Diastolic (Phase 4)

HIV (Phase 4)

Hyperglycemia (Phase 4)

Hypertrophy, Left Ventricular (Phase 3)

Hypoglycemia (Phase 2/Phase 3)

Hypopituitarism (Phase 4)

Hypothalamic Diseases (Phase 4)

Inflammation (Phase 1/Phase 2)

Insulin Resistance (Phase 4)

Ischemic Stroke (Phase 2)

Kidney Diseases (Phase 4)

Metabolic Syndrome (Phase 3)

Multiple System Atrophy (Phase 2)

Myocardial Infarction (Phase 4)

Non-alcoholic Fatty Liver Disease (Phase 4)

Obesity (Phase 4)

Obesity, Morbid (Phase 2/Phase 3)

Organ Dysfunction Scores (Phase 1/Phase 2)

Overweight (Phase 4)

Parkinson Disease (Phase 3)

Pediatric Obesity (Phase 3)

Pituitary Diseases (Phase 4)

Polycystic Ovary Syndrome (Phase 4)

Prediabetic State (Phase 4)

Psychological Distress (Phase 2/Phase 3)

Psychology, Clinical (Phase 4)

Psychotic Disorders (Phase 4)

Quality of Life (Phase 2/Phase 3)

Renal Insufficiency (Phase 1)

Renal Insufficiency, Chronic (Phase 3)

Schizophrenia (Phase 4)

Shock, Septic (Phase 1/Phase 2)

Short Bowel Syndrome (Phase 4)

Smoking Cessation (Phase 1/Phase 2)

Social Isolation (Phase 4)

Spinal Cord Injuries (Phase 4)

Stroke (Phase 2)

Weight Gain (Phase 4)

Weight Loss (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 284
  • # of Trial Organizations: 172

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue